Xu Yizhou, Wan Junjie, Wan Bin, Ding Haixia
School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China.
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Front Health Serv. 2025 Aug 29;5:1650709. doi: 10.3389/frhs.2025.1650709. eCollection 2025.
This study aims to develop a standardized multicriteria decision analysis (MCDA) framework tailored for implantable medical devices in China, addressing the challenges of inconsistent evaluation processes under China's evolving healthcare financing policies.
A mixed-methods design combining a discrete choice experiment (DCE) and MCDA was employed. Six criteria (clinical effectiveness, clinical safety, innovation, disease severity, implementation capacity, and cost) were identified through literature reviews and expert consultations. A DCE survey with 540 multi-stakeholder participants (decision-makers, HTA experts, clinicians, hospital administrators, and citizens) was conducted to derive criterion weights using mixed logit models. The framework was validated through a real-world case study assessing endoscopic linear staplers.
Clinical safety (35.45%) and cost (27.94%) emerged as the most critical criteria, followed by implementation capacity (16.56%) and clinical effectiveness (15.07%). Innovation (2.54%) and disease severity (2.44%) received minimal weight. The MCDA application demonstrated high inter-rater consistency (CV < 0.25).
This study proposes a transparent, stakeholder-driven framework for evaluating implantable medical devices, specifically designed to support China's healthcare policies. The framework ensures that healthcare decisions are grounded in clinical effectiveness, safety, and long-term economic viability.
本研究旨在开发一个针对中国可植入式医疗器械的标准化多标准决策分析(MCDA)框架,以应对在中国不断演变的医疗融资政策下评估过程不一致的挑战。
采用了一种结合离散选择实验(DCE)和MCDA的混合方法设计。通过文献综述和专家咨询确定了六个标准(临床有效性、临床安全性、创新性、疾病严重程度、实施能力和成本)。对540名多利益相关者参与者(决策者、卫生技术评估专家、临床医生、医院管理人员和公民)进行了DCE调查,以使用混合逻辑模型得出标准权重。通过评估内镜直线缝合器的实际案例研究对该框架进行了验证。
临床安全性(35.45%)和成本(27.94%)成为最关键的标准,其次是实施能力(16.56%)和临床有效性(15.07%)。创新性(2.54%)和疾病严重程度(2.44%)的权重最小。MCDA应用显示出较高的评分者间一致性(CV < 0.25)。
本研究提出了一个透明的、由利益相关者驱动的框架,用于评估可植入式医疗器械,专门设计用于支持中国的医疗政策。该框架确保医疗决策基于临床有效性、安全性和长期经济可行性。